Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Children with low HDL-c more likely to develop inflammatory bowel disease

12 Apr 2018
Children born via caesarean-section have an increased risk in developing childhood obesity and this has been linked to the lack of exposure to a mother’s gut bacteria.

Low serum concentrations of high-density lipoprotein cholesterol (HDL-c) during childhood is associated with subsequent inflammatory bowel disease (IBD), a recent study suggests.

The study included 3,551 children and adolescents whose body mass index (BMI), blood pressure, HDL-c levels, physical activity and C-reactive protein concentrations were measured at baseline in 1980. Participants were followed for subsequent IBD diagnoses, and a multivariable logistic regression model was used to determine significant risk factors for IBD.

After the final follow-up in 2011, 1.4 percent (n=49) of participants developed IBD, of whom 31 had ulcerative colitis, 12 had Crohn’s disease and six had undetermined colitis. Multivariate analysis revealed an inverse and significant relationship between childhood HDL-c and subsequent IBD diagnosis (odds ratio for each 1-standard deviation increase in HDL-c, 0.57; 95 percent CI, 0.39–0.82; p=0.006).

The results remained robust even after adjusting for levels of HDL-c in adulthood (p=0.003) and in sex-specific and outcome-specific analyses. HDL-c levels in adulthood were significantly lower in participants who developed IBD than in those who did not (1.22±0.32 vs 1.32±0.32 mmol/L; p=0.02).

Researchers then performed genotyping on the participants and found that the genetic z-scores 71 single nucleotide polymorphisms associated with elevated HDL-c concentrations were significantly lower in patients with IBD (p=0.01).

Future studies are needed to identify the underlying mechanisms that account for the association between HDL-c and IBD, and potentially provide therapeutic options, said researchers. Clinically, the findings may refine IBD prediction through the consideration of HDL-c information.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.